Cambridge Investment Research Advisors, Inc. Cassava Sciences Inc Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Cassava Sciences Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 10,719 shares of SAVA stock, worth $29,477. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,719

Holding current value

$29,477

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$9.57 - $35.08 $102,580 - $376,022	10,719 New	10,719 $315,000
Q4 2023 Feb 09, 2024	BUY	$12.64 - $30.11 $5,144 - $12,254	407 Added 4.06%	10,433 $235,000
Q3 2023 Oct 24, 2023	SELL	$16.64 - $25.32 $32,281 - $49,120	-1,940 Reduced 16.21%	10,026 $167,000
Q2 2023 Jul 13, 2023	SELL	$21.59 - $27.88 $60,452 - $78,064	-2,800 Reduced 18.96%	11,966 $293,000
Q1 2023 May 11, 2023	BUY	$23.46 - $36.44 $30,685 - $47,663	1,308 Added 9.72%	14,766 $356,000
Q4 2022 Feb 08, 2023	SELL	$27.82 - $44.16 $31,993 - $50,783	-1,150 Reduced 7.87%	13,458 $398,000
Q3 2022 Oct 17, 2022	BUY	$16.33 - $51.06 $13,161 - $41,154	806 Added 5.84%	14,608 $610,000
Q2 2022 Jul 13, 2022	SELL	$17.22 - $38.47 $36,007 - $80,440	-2,091 Reduced 13.16%	13,802 $388,000
Q1 2022 May 12, 2022	SELL	$32.6 - $53.05 $4,694 - $7,639	-144 Reduced 0.9%	15,893 $590,000
Q4 2021 Feb 03, 2022	SELL	$36.77 - $90.91 $119,649 - $295,821	-3,254 Reduced 16.87%	16,037 $700,000
Q3 2021 Nov 02, 2021	BUY	$41.79 - $135.3 $442,681 - $1.43 Million	10,593 Added 121.79%	19,291 $1.2 Million
Q2 2021 Aug 10, 2021	BUY	$32.15 - $89.72 $279,640 - $780,384	8,698 New	8,698 $743,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account

Cambridge Investment Research Advisors, Inc. Cassava Sciences Inc Transaction History